Sputum Candida albicans Presages FEV1 Decline and Hospital-Treated Exacerbations in Cystic Fibrosis

被引:144
|
作者
Chotirmall, Sanjay H. [1 ]
O'Donoghue, Elaine
Bennett, Kathleen [2 ]
Gunaratnam, Cedric
O'Neill, Shane J.
McElvaney, Noel G.
机构
[1] Royal Coll Surgeons Ireland, Beaumont Hosp, Resp Res Div, Educ & Res Ctr,Dept Resp Med, Dublin 9, Ireland
[2] St James Hosp, Trinity Ctr Hlth Sci, Dept Pharmacol & Therapeut, Dublin 8, Ireland
关键词
ASPERGILLUS-FUMIGATUS; ADULT PATIENTS; BRONCHOPULMONARY ASPERGILLOSIS; PULMONARY-FUNCTION; IMMUNE-RESPONSE; IDENTIFICATION; DUBLINIENSIS; PREVALENCE; TOBRAMYCIN; INFECTION;
D O I
10.1378/chest.09-2996
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: The role of Candida albicans in the cystic fibrosis (CF) airway is underexplored. Considered a colonizer, few question its pathogenic potential despite high isolation frequencies from sputum culture. We evaluated the frequency and identified the strongest predictors of C albicans colonization in CF. Independent associations of colonization with clinical outcomes were determined, and the longitudinal effects of C albicans acquisition on BMI and FEV1 were evaluated. Methods: A prospective observational study of 89 patients with CF was performed (3,916 sputum samples over 11 years). Frequency of C albicans growth in sputum allowed classification of the cohort into colonizers and noncolonizers. BMI, FEV1, hospital-treated exacerbations, and other clinical parameters were followed throughout the study to determine association with colonization status. Multivariate regression determined the strongest predictors of colonization and for clinical effects after adjustment for confounders. Repeated-measures analysis of variance assessed the longitudinal effect of colonization on BMI and FEV1. Results: Colonization with C albicans was frequent (49.4%) and best predicted by pancreatic insufficiency (P = .014), osteopenia (P = .03), and cocolonization with Pseudomonas species (P = .002). C albicans colonization significantly predicted hospital-treated exacerbations (P = .004) after adjustment for confounders. Exacerbation rate significantly increased in patients with chronic or intermittent colonizations following first acquisition of C albicans. Colonization accelerated rates of decline for BMI (P < .0001) and FEV1 (P < .001). Conclusion: Airway colonization with C albicans presaged a greater rate of FEV1 decline and hospital-treated exacerbations in CF. CHEST 2010; 138(5):1186-1195
引用
收藏
页码:1186 / 1195
页数:10
相关论文
共 25 条
  • [1] Recurrent exacerbations affect FEV1 decline in adult patients with cystic fibrosis
    Amadori, Anna
    Antonelli, Andrea
    Balteri, Ilaria
    Schreiber, Anja
    Bugiani, Massimiliano
    De Rose, Virginia
    RESPIRATORY MEDICINE, 2009, 103 (03) : 407 - 413
  • [2] Induced sputum nitrites correlate with FEV1 in children with cystic fibrosis
    Anil, N.
    Singh, M.
    Rajwanshi, A.
    Vohra, H.
    ACTA PAEDIATRICA, 2010, 99 (05) : 711 - 714
  • [3] Risk factors for rate of decline in FEV1 in adults with cystic fibrosis
    Konstan, Michael W.
    Wagener, Jeffrey S.
    VanDevanter, Donald R.
    Pasta, David J.
    Yegin, Ashley
    Rasouliyan, Lawrence
    Morgan, Wayne J.
    JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (05) : 405 - 411
  • [4] Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis
    Konstan, Michael W.
    Schluchter, Mark D.
    Xue, Wei
    Davis, Pamela B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (11) : 1084 - 1089
  • [5] Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry
    Kerem, Eitan
    Viviani, Laura
    Zolin, Anna
    MacNeill, Stephanie
    Hatziagorou, Elpis
    Ellemunter, Helmut
    Drevinek, Pavel
    Gulmans, Vincent
    Krivec, Uros
    Olesen, Hanne
    EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (01) : 125 - 133
  • [6] Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint
    Konstan, M. W.
    Wagener, J. S.
    Yegin, A.
    Millar, S. J.
    Pasta, D. J.
    VanDevanter, D. R.
    JOURNAL OF CYSTIC FIBROSIS, 2010, 9 (05) : 332 - 338
  • [7] Cystic fibrosis patients at risk for disease progression marked by decline in FEV1% predicted: development of the cystic fibrosis risk of disease progression score
    Marsteller, Nathan L.
    Nussbaum, Eliezer
    Morphew, Tricia
    Randhawa, Inderpal S.
    JOURNAL OF THORACIC DISEASE, 2019, 11 (12) : 5557 - 5565
  • [8] Clinical Use of Dornase Alfa Is Associated With a Slower Rate of FEV1 Decline in Cystic Fibrosis
    Konstan, Michael W.
    Wagener, Jeffrey S.
    Pasta, David J.
    Millar, Stefanie J.
    Jacobs, Joan R.
    Yegin, Ashley
    Morgan, Wayne J.
    PEDIATRIC PULMONOLOGY, 2011, 46 (06) : 545 - 553
  • [9] Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor
    Fidler, Meredith C.
    Beusmans, Jack
    Panorchan, Paul
    Van Goor, Fredrick
    JOURNAL OF CYSTIC FIBROSIS, 2017, 16 (01) : 41 - 44
  • [10] Global Lung Function Initiative equations improve interpretation of FEV1 decline among patients with cystic fibrosis
    Stanojevic, Sanja
    Bilton, Diana
    McDonald, Alexandra
    Stocks, Janet
    Aurora, Paul
    Prasad, Ammani
    Cole, Tim J.
    Davies, Gwyneth
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (01) : 262 - 264